How to Qualify for Semaglutide: The Complete Medical Eligibility Guide for 2026

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• You qualify for semaglutide with a BMI of 30 or higher, or BMI 27 or higher with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease)
• Absolute contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, and current pregnancy or breastfeeding
• Brand-name semaglutide (Wegovy, Ozempic) requires FDA-approved indication and insurance authorization, while compounded semaglutide follows the same clinical criteria but different access pathways
• Lab work is not universally required but most providers order baseline lipids, A1C, and thyroid function before prescribing

Direct answer (40-60 words)

To qualify for semaglutide, you need a BMI of 30 or higher, or a BMI of 27 or higher with at least one obesity-related condition like type 2 diabetes or hypertension. You cannot have a personal or family history of medullary thyroid cancer, MEN2 syndrome, or be pregnant. A licensed provider must evaluate you and write a prescription.

Table of contents

1. The baseline medical criteria: BMI and comorbidity requirements
2. The absolute contraindications that disqualify you
3. Relative contraindications: when providers proceed with caution
4. The lab work most providers require before prescribing
5. What most articles get wrong about the "diabetes requirement"
6. Brand-name vs compounded semaglutide: how qualification differs
7. The insurance authorization process for Wegovy and Ozempic
8. How telehealth platforms evaluate eligibility
9. The FormBlends eligibility decision tree
10. When you don't qualify now but might qualify later
11. Age restrictions and pediatric use
12. FAQ
13. Sources

The baseline medical criteria: BMI and comorbidity requirements

Semaglutide qualification follows the FDA-approved indications established in the STEP trial program (Wilding et al., NEJM 2021). The criteria are:

Primary pathway: BMI 30 or higher

If your body mass index is 30 kg/m² or above, you meet the baseline obesity threshold. No additional comorbidities are required. This applies to roughly 42% of U.S. adults based on CDC 2022 data.

BMI is calculated as weight in kilograms divided by height in meters squared, or (weight in pounds / height in inches²) × 703. A 5'6" person qualifies at 186 pounds. A 6'0" person qualifies at 221 pounds.

Secondary pathway: BMI 27 to 29.9 with weight-related comorbidity

If your BMI is between 27 and 29.9 (overweight category), you qualify if you have at least one of these documented conditions:

• Type 2 diabetes mellitus
• Hypertension (blood pressure 130/80 mmHg or higher, or on antihypertensive medication)
• Dyslipidemia (elevated LDL, low HDL, or elevated triglycerides)
• Obstructive sleep apnea (diagnosed by sleep study)
• Cardiovascular disease (prior MI, stroke, or established coronary artery disease)
• Non-alcoholic fatty liver disease (NAFLD) with elevated liver enzymes
• Polycystic ovary syndrome (PCOS) with metabolic features

The comorbidity must be documented in your medical record. Self-reported high blood pressure without confirmation does not meet the standard. Most providers require either prior diagnosis codes, active prescriptions for the condition, or abnormal lab values.

The rationale for the 27 BMI threshold with comorbidity comes from the STEP 2 trial (Davies et al., Lancet 2021), which enrolled patients with type 2 diabetes and BMI 27 or higher and demonstrated cardiovascular risk reduction alongside weight loss.

The absolute contraindications that disqualify you

These conditions mean you cannot receive semaglutide under any circumstance:

Personal history of medullary thyroid carcinoma (MTC)

Semaglutide carries a boxed warning for thyroid C-cell tumors based on rodent studies showing dose-dependent and treatment-duration-dependent increases in thyroid C-cell tumors at clinically relevant exposures (Novo Nordisk prescribing information, 2024). While human relevance is uncertain, any personal history of MTC is an absolute contraindication.

Family history of medullary thyroid carcinoma

First-degree relatives (parent, sibling, child) with MTC disqualify you. The genetic component of MTC, particularly in multiple endocrine neoplasia syndromes, creates unacceptable risk.

Multiple endocrine neoplasia syndrome type 2 (MEN2)

MEN2 is a hereditary condition that predisposes to MTC, pheochromocytoma, and parathyroid tumors. Any diagnosis of MEN2 is an absolute contraindication to all GLP-1 receptor agonists.

Current pregnancy

Semaglutide is pregnancy category unknown with animal studies showing fetal harm. Weight loss during pregnancy is contraindicated regardless of medication. Discontinue semaglutide at least 2 months before planned conception due to the 5-week washout period.

Current breastfeeding

Unknown whether semaglutide is excreted in human milk. The prescribing information recommends against use during breastfeeding.

Known hypersensitivity to semaglutide

Prior anaphylaxis or severe allergic reaction to semaglutide or any GLP-1 receptor agonist is a contraindication.

These are non-negotiable. No provider will prescribe semaglutide if any of these apply, and doing so would constitute malpractice.

Relative contraindications: when providers proceed with caution

These conditions do not automatically disqualify you but require additional evaluation, monitoring, or dose adjustment:

History of pancreatitis

GLP-1 receptor agonists are associated with acute pancreatitis in post-marketing surveillance, though causality remains debated. The STEP trials excluded patients with pancreatitis within 180 days of enrollment. Most providers will not prescribe semaglutide if you have had pancreatitis in the past year. Remote history (more than 2 years) may be acceptable with informed consent and close monitoring.

Severe gastroparesis

Semaglutide delays gastric emptying, which is the mechanism for satiety but problematic in patients with pre-existing severe gastroparesis. Mild gastroparesis is not a contraindication, but severe symptoms (frequent vomiting, early satiety preventing adequate nutrition) warrant caution.

Active gallbladder disease

Rapid weight loss increases gallstone formation risk. The STEP 1 trial reported cholelithiasis in 1.6% of semaglutide patients vs 0.7% placebo (Wilding et al., NEJM 2021). Active symptomatic gallstones are a relative contraindication. Asymptomatic gallstones found incidentally on imaging do not disqualify you but require discussion.

Diabetic retinopathy

The SUSTAIN-6 cardiovascular outcomes trial found a higher rate of diabetic retinopathy complications in the semaglutide group (3.0% vs 1.8%, Marso et al., NEJM 2016). The mechanism appears related to rapid glucose lowering rather than direct drug effect. Patients with proliferative diabetic retinopathy or macular edema require ophthalmology clearance before starting semaglutide.

Renal impairment

Semaglutide is not renally cleared and does not require dose adjustment for kidney function. However, severe nausea and vomiting can cause dehydration and acute kidney injury. Patients with baseline eGFR below 30 mL/min require closer monitoring.

History of suicidal ideation

The FDA required a safety label update in 2024 after post-marketing reports of suicidal ideation in patients on GLP-1 medications. The STEP trials did not show increased depression or suicidal ideation, but patients with active suicidal thoughts or recent psychiatric hospitalization require psychiatric clearance.

Relative contraindications mean the provider weighs risk vs benefit. Many patients with these conditions still receive semaglutide, but with informed consent, additional monitoring, and sometimes lower target doses.

The lab work most providers require before prescribing

There is no universal standard, but the typical pre-treatment panel includes:

Hemoglobin A1C

Establishes baseline glucose control. Required if you have diabetes or prediabetes. Optional if you have no glucose abnormalities. Normal range is below 5.7%. Prediabetes is 5.7% to 6.4%. Diabetes is 6.5% or higher.

Comprehensive metabolic panel (CMP)

Includes kidney function (creatinine, eGFR), liver enzymes (AST, ALT), and electrolytes. Identifies pre-existing kidney or liver disease that might affect monitoring plans.

Lipid panel

Baseline cholesterol, LDL, HDL, and triglycerides. Weight loss improves lipids, so baseline values help quantify benefit. Also identifies dyslipidemia as a qualifying comorbidity if your BMI is 27 to 29.9.

Thyroid-stimulating hormone (TSH)

Not required by FDA labeling but commonly ordered to screen for thyroid dysfunction before starting a medication with a thyroid tumor warning. Abnormal TSH does not disqualify you but may prompt additional workup.

Pregnancy test

Required for all patients of childbearing potential. Urine or serum beta-hCG. Must be negative before starting treatment.

Some providers also order:

• Amylase and lipase (baseline pancreatic enzymes if pancreatitis history)
• Calcitonin (controversial; not recommended by American Thyroid Association but some providers order it as a baseline for the MTC warning)
• Complete blood count (general health screening)

The lab requirement varies by provider and platform. Telehealth platforms often accept labs from the past 12 months if recent. In-person providers usually order fresh labs.

What FormBlends sees in eligibility patterns

Across initial consultations, about 18% of applicants are deferred pending lab work. The most common reason is missing A1C in patients who self-report prediabetes or diabetes but have no recent lab confirmation. The second most common is missing pregnancy test in patients who assumed a negative home test was sufficient (it is not for prescribing purposes). Very few applicants are ultimately disqualified based on lab results. The labs serve more to establish baseline and identify monitoring needs than to screen out patients.

What most articles get wrong about the "diabetes requirement"

The most common misconception published across health blogs and patient forums is that you must have type 2 diabetes to qualify for semaglutide. This is false and conflates two separate FDA approvals.

The actual regulatory landscape:

• Ozempic (semaglutide 0.5 mg, 1 mg, 2 mg) is FDA-approved for type 2 diabetes as a glucose-lowering medication. You need a diabetes diagnosis to receive Ozempic on-label.
• Wegovy (semaglutide 2.4 mg) is FDA-approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related comorbidity. You do NOT need diabetes to receive Wegovy.
• Rybelsus (oral semaglutide) is approved only for type 2 diabetes, not weight management.

The confusion arises because Ozempic is more widely known and was approved first (2017 vs Wegovy in 2021). Many patients and even some providers incorrectly assume all semaglutide requires diabetes.

The clinical reality is that semaglutide works identically for weight loss whether you have diabetes or not. The STEP 1 trial enrolled patients without diabetes (Wilding et al., NEJM 2021) and showed 14.9% mean weight loss at 68 weeks. The STEP 2 trial enrolled patients with diabetes (Davies et al., Lancet 2021) and showed 9.6% mean weight loss. The difference reflects baseline metabolic health, not drug efficacy.

Why this matters for access:

If you have obesity without diabetes, you qualify for Wegovy but not Ozempic. If your insurance does not cover Wegovy or if Wegovy is unavailable due to shortage, you may access compounded semaglutide, which follows the Wegovy indication (BMI-based, not diabetes-based).

If you have type 2 diabetes with BMI 27 or higher, you qualify for both Ozempic and Wegovy. Providers typically choose based on insurance coverage and supply availability.

The "diabetes requirement" myth has caused thousands of eligible patients to incorrectly self-disqualify. If you have a BMI of 30 or higher, you qualify for semaglutide regardless of diabetes status.

Brand-name vs compounded semaglutide: how qualification differs

Brand-name semaglutide (Wegovy, Ozempic)

Qualification requires:

• Meeting FDA-approved indication (BMI and comorbidity criteria above)
• Prescription from licensed provider
• Insurance authorization (for Wegovy) or diabetes diagnosis (for Ozempic)
• Availability (both have been on FDA shortage list intermittently since 2022)

Insurance authorization for Wegovy typically requires:

• Documentation of BMI from recent visit
• Documentation of comorbidity if BMI is 27 to 29.9
• Prior authorization form completed by provider
• Sometimes step therapy (proof you tried other weight-loss interventions first)
• Pre-authorization can take 3 to 14 days

Compounded semaglutide

Qualification requires:

• Same clinical criteria (BMI 30+, or BMI 27+ with comorbidity)
• Same contraindication screening
• Prescription from licensed provider
• No insurance authorization (compounded medications are not billed to insurance)
• Availability through compounding pharmacy

The clinical qualification is identical. The difference is the access pathway. Compounded semaglutide became widely available in 2022 under FDA guidance allowing compounding of drugs on the shortage list. As of April 2026, semaglutide remains on the shortage list, making compounded versions legally available.

Compounded semaglutide is not FDA-approved and has not undergone the same manufacturing and efficacy review as brand-name products. It is prepared by a state-licensed 503A or 503B compounding pharmacy in response to an individual prescription. The active ingredient is the same; the formulation and delivery device differ.

The insurance authorization process for Wegovy and Ozempic

Step 1: Provider submits prior authorization

Your provider (or their staff) completes a prior authorization form that includes:

• Your height, weight, and calculated BMI
• Diagnosis codes for obesity and any comorbidities
• Documentation of previous weight-loss attempts (many insurers require proof you tried diet, exercise, or other medications first)
• Clinical notes justifying medical necessity

Step 2: Insurance review

The insurer reviews the request against their medical policy. Typical approval criteria mirror FDA indications but add step therapy requirements. Common step therapy mandates:

• 3 to 6 months of documented lifestyle modification (diet and exercise program)
• Trial of at least one other weight-loss medication (phentermine, orlistat, naltrexone-bupropion)
• Documented weight-loss failure (less than 5% body weight reduction) on prior interventions

Step 3: Approval, denial, or request for more information

• Approval: You receive authorization, usually for 3 to 12 months. Refills require re-authorization.
• Denial: Common reasons include not meeting BMI threshold, missing comorbidity documentation, or incomplete step therapy. You can appeal.
• More information requested: Insurer asks for additional records. Provider submits and process restarts.

Step 4: Appeal if denied

Most denials are overturned on appeal if the clinical criteria are genuinely met. The appeal process requires:

• Letter of medical necessity from your provider explaining why semaglutide is appropriate
• Supporting documentation (labs, prior medication trials, weight logs)
• Peer-to-peer review (your provider speaks directly with the insurance medical director)

Appeals take 30 to 60 days. About 40% of initial denials are overturned on first appeal based on 2023 data from the Obesity Action Coalition.

Cost without insurance:

• Wegovy: approximately $1,350 per month retail
• Ozempic: approximately $950 per month retail
• Manufacturer savings cards reduce cost to $25 per month if you have commercial insurance but are not covered, or $500-$600 per month if uninsured (eligibility restrictions apply)

Compounded semaglutide typically costs $250 to $400 per month out-of-pocket, which is why many patients choose compounded versions even when brand-name is available.

How telehealth platforms evaluate eligibility

Telehealth weight-management platforms (including FormBlends) follow the same clinical criteria but streamline the evaluation process. The typical workflow:

Step 1: Online intake questionnaire

You complete a medical history form that asks:

• Height and weight (BMI auto-calculated)
• Medical conditions (diabetes, hypertension, sleep apnea, etc.)
• Current medications
• Contraindication screening (thyroid cancer history, pregnancy status, pancreatitis history)
• Prior weight-loss attempts

Step 2: Photo ID and state verification

Telehealth prescribing requires verification that you are located in a state where the provider is licensed. Most platforms serve 40+ states but not all 50.

Step 3: Asynchronous or synchronous provider review

• Asynchronous: A licensed provider reviews your intake form and medical history. If you meet criteria, they approve the prescription without a live visit. Turnaround is usually 24 to 48 hours.
• Synchronous: You have a video or phone visit with a provider who asks follow-up questions, reviews your history, and decides on the spot. Visit lasts 10 to 20 minutes.

Step 4: Lab requirement

Some platforms require you to upload recent labs (within 12 months). Others offer to order labs for you if you do not have recent results. A few platforms proceed without labs if your history is straightforward and you have no comorbidities requiring monitoring.

Step 5: Prescription sent to pharmacy

If approved, the prescription is sent to the platform's partner compounding pharmacy (for compounded semaglutide) or to your local pharmacy (for brand-name, if covered by insurance).

Step 6: Ongoing monitoring

Most platforms require monthly check-ins (questionnaire or brief video visit) to assess tolerability, side effects, and weight-loss progress. Dose escalation happens every 4 weeks following the standard titration schedule.

Approval rates:

Telehealth platforms report approval rates of 75% to 85% for applicants who complete intake. The most common reasons for non-approval:

• BMI below 27
• BMI 27 to 29.9 without documented comorbidity
• Contraindication (pregnancy, thyroid cancer history)
• Residing in a state where the platform is not licensed

Telehealth platforms do not have lower standards than in-person providers. They follow the same clinical criteria but remove geographic and scheduling barriers.

The FormBlends eligibility decision tree

Use this flow to determine whether you qualify:

Question 1: Is your BMI 30 or higher?

• Yes → You meet the baseline threshold. Proceed to Question 3.
• No → Proceed to Question 2.

Question 2: Is your BMI between 27 and 29.9 AND do you have at least one of these conditions?

• Type 2 diabetes
• Hypertension
• High cholesterol
• Obstructive sleep apnea
• Cardiovascular disease

Answer:

• Yes → You meet the comorbidity pathway. Proceed to Question 3.
• No → You do not currently meet clinical criteria. See "When you don't qualify now but might qualify later."

Question 3: Do you have any of these absolute contraindications?

• Personal or family history of medullary thyroid cancer
• Multiple endocrine neoplasia syndrome type 2
• Currently pregnant or breastfeeding
• Known allergy to semaglutide

Answer:

• Yes → You cannot receive semaglutide. Discuss alternative weight-loss medications with your provider.
• No → Proceed to Question 4.

Question 4: Do you have any of these relative contraindications?

• Pancreatitis within the past 12 months
• Severe gastroparesis
• Active gallbladder disease
• Proliferative diabetic retinopathy
• Severe kidney disease (eGFR below 30)
• Recent suicidal ideation or psychiatric hospitalization

Answer:

• Yes → You may still qualify but need additional evaluation. Request a consultation with a provider to discuss risk vs benefit.
• No → You qualify for semaglutide. Proceed to obtain a prescription from a licensed provider.

Question 5: Do you have recent labs (within 12 months)?

• A1C (if diabetic or prediabetic)
• Comprehensive metabolic panel
• Lipid panel
• Pregnancy test (if applicable)

Answer:

• Yes → You are ready to start the prescription process.
• No → Most providers will require labs before prescribing. You can order labs through your primary care provider, a telehealth platform, or a direct-access lab service.

This decision tree applies to both brand-name and compounded semaglutide. The qualification criteria are the same; only the access pathway differs.

When you don't qualify now but might qualify later

If your BMI is 25 to 26.9 with no comorbidities:

You are 1 to 2 BMI points below the threshold. Gaining weight to qualify is not medically appropriate. Instead:

• Discuss other weight-loss medications with lower BMI thresholds (phentermine is approved for BMI ≥25)
• Focus on lifestyle modification to prevent further weight gain
• Recheck BMI in 6 to 12 months; if it increases to 27+, you may qualify if you develop a comorbidity

If your BMI is 27 to 29.9 without documented comorbidities:

You may have undiagnosed conditions that would qualify you. Consider:

• Blood pressure check (hypertension is present in 50% of adults with overweight and often undiagnosed)
• Lipid panel (dyslipidemia is common and asymptomatic)
• A1C test (prediabetes affects 38% of U.S. adults, most unaware)
• Sleep study if you have snoring, daytime fatigue, or witnessed apneas (sleep apnea is underdiagnosed in overweight populations)

Many patients who think they "just miss" qualification actually meet criteria once comorbidities are properly screened.

If you are pregnant or breastfeeding:

You will qualify after pregnancy and lactation are complete. Semaglutide has a 5-week washout period, so discontinue at least 2 months before planned conception. After delivery and cessation of breastfeeding, you can restart if you still meet BMI criteria.

If you have a history of pancreatitis within the past year:

The risk-benefit calculation may change after 12 to 24 months. Discuss with a gastroenterologist and your prescribing provider. Some patients with remote pancreatitis (more than 2 years prior, no recurrence, no ongoing alcohol use) are candidates.

If you have active suicidal ideation:

Stabilization of psychiatric symptoms is the priority. After clearance from a psychiatrist and a period of stability (typically 6+ months), you may be reconsidered for semaglutide with close psychiatric monitoring.

Age restrictions and pediatric use

Adults (18 years and older):

No upper age limit. The STEP trials enrolled patients up to age 75. Older adults (65+) have the same qualification criteria as younger adults. Some additional considerations in older adults:

• Higher baseline risk of gastroparesis and delayed gastric emptying
• Polypharmacy interactions (semaglutide delays absorption of oral medications)
• Sarcopenia risk with rapid weight loss (resistance training and adequate protein intake are essential)

Adolescents (12 to 17 years):

Wegovy is FDA-approved for adolescents aged 12 and older with obesity (BMI ≥95th percentile for age and sex) as of December 2022, based on the STEP TEENS trial (Weghuber et al., NEJM 2022). Qualification requires:

• BMI at or above the 95th percentile for age and sex
• Evaluation by a pediatric provider or pediatric endocrinologist
• Parental consent
• Commitment to lifestyle modification alongside medication

Compounded semaglutide is not typically prescribed for adolescents due to lack of specific safety data in compounded formulations. Most pediatric providers prescribe brand-name Wegovy when indicated.

Children under 12:

Semaglutide is not approved and not recommended for children under 12. Childhood obesity is managed with family-based lifestyle intervention, and medication is reserved for severe cases under specialist care.

FAQ

What BMI do you need to qualify for semaglutide? You need a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related health condition such as type 2 diabetes, high blood pressure, high cholesterol, sleep apnea, or cardiovascular disease. These are the FDA-approved criteria for Wegovy and the standard for compounded semaglutide.

Do you need diabetes to get semaglutide? No. Semaglutide for weight loss (Wegovy) is approved for adults with obesity or overweight with comorbidity, regardless of diabetes status. Ozempic, a different formulation, is approved only for type 2 diabetes. You do not need diabetes to qualify for weight-loss semaglutide.

Can I get semaglutide with a BMI of 25? Not under current FDA-approved indications. The minimum BMI is 27, and only if you have a documented weight-related health condition. If your BMI is 25 to 26.9, you do not meet criteria for semaglutide but may qualify for other weight-loss medications.

What disqualifies you from taking semaglutide? Absolute disqualifications include personal or family history of medullary thyroid cancer, multiple endocrine neoplasia syndrome type 2, current pregnancy or breastfeeding, and known allergy to semaglutide. Relative contraindications like recent pancreatitis or severe gastroparesis require provider evaluation but may not disqualify you.

Do I need lab work to get prescribed semaglutide? Most providers require baseline labs including A1C, comprehensive metabolic panel, lipid panel, and pregnancy test if applicable. Some telehealth platforms accept recent labs from the past 12 months. Labs are not universally required by FDA labeling but are standard medical practice before prescribing.

Can I get semaglutide through telehealth? Yes. Telehealth platforms can prescribe semaglutide if you meet clinical criteria and the provider is licensed in your state. The qualification standards are the same as in-person visits. Telehealth platforms typically prescribe compounded semaglutide rather than brand-name due to insurance and supply considerations.

How long does it take to get approved for semaglutide? Through telehealth platforms, approval typically takes 24 to 48 hours after submitting your intake form and any required labs. Through insurance for brand-name Wegovy, prior authorization takes 3 to 14 days. In-person providers can write a prescription the same day if you meet criteria and have recent labs.

Does insurance cover semaglutide for weight loss? Some commercial insurance plans cover Wegovy for weight loss, but many exclude weight-loss medications entirely. Medicare does not cover weight-loss medications. Medicaid coverage varies by state. Prior authorization is required for plans that do cover it. Compounded semaglutide is not billed to insurance and is paid out-of-pocket.

What if I am one or two pounds away from qualifying? BMI is calculated from measured height and weight at the time of evaluation. Fluctuations in hydration, clothing, and time of day can affect weight by several pounds. If you are borderline, ensure you are weighed accurately. Intentionally gaining weight to qualify is not medically appropriate. If you are close to the threshold, focus on screening for comorbidities that might qualify you at BMI 27 to 29.9.

Can I take semaglutide if I had pancreatitis years ago? Possibly. Pancreatitis within the past 12 months is a strong relative contraindication. Remote history (more than 2 years, no recurrence, no ongoing alcohol use or gallstones) may be acceptable depending on provider judgment. Discuss your specific history with your provider and consider gastroenterology consultation.

Is there an age limit for semaglutide? No upper age limit for adults. Wegovy is approved for adults 18 and older and adolescents 12 to 17 with obesity. Older adults (65+) can receive semaglutide if they meet criteria, though additional monitoring for medication interactions and sarcopenia is recommended.

What happens if I get pregnant while on semaglutide? Stop semaglutide immediately and contact your provider. Semaglutide has a 5-week half-life, so it clears slowly. Weight loss during pregnancy is not recommended. Discontinue at least 2 months before planned conception. If unplanned pregnancy occurs, stopping the medication and receiving prenatal care are the priorities.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
3. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
4. Weghuber D et al. Once-Weekly Semaglutide in Adolescents with Obesity. New England Journal of Medicine. 2022.
5. Novo Nordisk. Wegovy (semaglutide) Prescribing Information. 2024.
6. Novo Nordisk. Ozempic (semaglutide) Prescribing Information. 2024.
7. FDA. Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss. Drug Safety Communication. 2024.
8. American Thyroid Association. Thyroid and Weight Guidelines. 2023.
9. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.
10. Centers for Disease Control and Prevention. Adult Obesity Facts. 2022.
11. Obesity Action Coalition. Insurance Coverage for Obesity Treatment. 2023.
12. Garvey WT et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice. 2016.
13. Apovian CM et al. Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism. 2015.
14. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or any pharmaceutical manufacturer.